Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...

It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.

Following billionaire investors isn't as difficult as you might imagine thanks to quarterly reporting required by the ...

Given its low valuation and the seeming overreaction in the markets to the recent trial results, this is a stock that could ...

A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...

The Nordic region accounts for about 1% of the world’s GDP and 0.3% of its population. Yet it has produced an impressive list ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.

Novo Nordisk’s obesity drug CagriSema’s test results showed an average weight loss of over 20%, but its stock slid in ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we ...